Cytochrome P450 enzymes: novel options for cancer therapeutics.
The concept of overexpression of individual forms of cytochrome P450 enzymes in tumor cells is now becoming well recognized. Indeed, a growing body of research highlights the overexpression of P450s, particularly CYP1B1, in tumor cells as representing novel targets for anticancer therapy. The purpose of this review is to outline the novel therapeutic options and opportunities arising from both enhanced endogenous expression of cytochrome P450 in tumors and cytochrome P450-mediated gene therapy.
McFadyen
Morag C E
MC
Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom. m.mcfadyen@abdn.ac.uk
Melvin
William T
WT
Murray
Graeme I
GI
D000970:Antineoplastic Agents / Q000494:pharmacology*; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D011110:Polymorphism, Genetic; D012333:RNA, Messenger / Q000378:metabolism
D000970:Antineoplastic Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D012333:RNA, Messenger; D003577:Cytochrome P-450 Enzyme System